Propanc Biopharma, Inc. Common Stock (PPCB) — Tangible Net Worth Ratio
Propanc Biopharma, Inc. Common Stock (PPCB) has a Tangible Net Worth Ratio of 100.0% as of December 2025. This metric is calculated by deducting intangible assets ($0.00) from net assets ($10.45 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Propanc Biopharma, Inc. Common Stock short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Propanc Biopharma, Inc. Common Stock Tangible Net Worth Ratio (2011–2025)
This chart shows how Propanc Biopharma, Inc. Common Stock's Tangible Net Worth Ratio has changed across 2 annual periods from 2011 to 2025. As of December 2025, the ratio stands at 100.0%, reflecting net assets of $10.45 Million with intangible assets of $0.00 USD. See PPCB days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Propanc Biopharma, Inc. Common Stock (2011–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Propanc Biopharma, Inc. Common Stock from 2011 to 2025, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see PPCB stock market capitalisation.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 100.0% | $13.91 Million | $0.00 | $19.63 Million | ▲ +0.3 pp |
| 2011 | 99.7% | $10.51 Million | $27.56K | $10.81 Million | — |